Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth

Molecular and Cellular Biology

Volumn 17, Issue 7, 1997, Pages 3629-3639

  Nakshatri, Harikrishna ^a,b   Bhat Nakshatri, Poornima ^a   Martin, Daniel A ^a   Goulet Jr , Robert J ^a   Sledge Jr , George W ^a  

^a INDIANA UNIVERSITY   (United States)

^b Department of Pharmacology and Toxicology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CELL MIGRATION; COMPLEMENT ACTIVATION; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE REPRESSION; HORMONE DEPENDENCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALIA;

EID: 0030927167     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/mcb.17.7.3629     Document Type: Article

References (68)

1. Angel, P., I. Baumann, B. Stein, H. Delius, H. J. Rahmsdorf, and P. Herrlich. 1987. 12-O-Tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5′-flanking region. Mol. Cell. Biol. 7:2256-2266.
2. Astruc, M. E., C. Chabret, P. Bali, D. Gagne, and M. Pons. 1995. Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor. Endocrinology 136:824-832.
3. Azzam, H. S., G. Arand, M. E. Lippman, and E. W. Thompson. 1993. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell line independent of MMP-2 production. J. Natl. Cancer Inst. 85:1758-1764.
4. Baeuerle, P. A., and T. Henkel. 1994. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12:141-179.
5. Baeuerle, P. A., and D. Baltimore. 1996. NF-κB: ten years after. Cell 87:13-20.
6. Beg, A. A., and D. Baltimore. 1996. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274:782-784.
7. Blasi, F. 1993. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 15:105-111.
8. Brooks, P. C., S. Stromblad, L. C. Sanders, T. L. von Schalscha, R. T. Aimes, W. G. Stetler-Stevenson, J. P. Quigley, and D. A. Cheresh. 1996. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αVβ3. Cell 85:683-693.
9. Clark, G. M., and W. L. McGuire. 1988. Steroid receptors and other prognostic factors in primary breast cancer. Semin. Oncol. 15:20-25.
10. Clark, R., E. W. Thompson, F. Leonessa, J. Lippman, M. McGarvey, T. L. Frandsen, and N. Brunner. 1993. Hormone resistance, invasiveness and metastatic potential in breast cancer. Breast Cancer Res. Treat. 24:227-239.
11. Dejardin, E., G. Bonizzi, A. Bellahcene, V. Castronovo, M.-P. Merville, and V. Bours. 1995. Highly-expressed p100/p52 (NFκB2) sequesters other NF-κB-related proteins in the cytoplasm of human cancer cells. Oncogene 11: 1835-1841.
12. Deloukas, P., and A. P. G. M. van Loon. 1993. Genomic organization of the gene encoding the p65 subunit of NF-κB: multiple variants of the p65 protein may be generated by alternative splicing. Hum. Mol. Genet. 2:1895-1900.
13. Dobrzanski, P., R.-P. Ryseck, and R. Bravo. 1995. Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100. Oncogene 10:1003-1007.
14. Duffy, M. J., M. P. O'Grady, D. Devaney, L. O'Siorain, J. J. Fennelry, and H. J. Lijnen. 1988. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer 62:531-533.
15. Duffy, M. J., D. Reilly, E. McDermott, N. O'Higgins, J. J. Fennelly, and P.A. Andreasen. 1994. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 74:2276-2280
16. Dumont, J. A., A. J. Bitonti, C. D. Wallace, R. J. Baumann, E. A. Cashman, and D. E. Cross-Doersen. 1996. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ. 7:351-359.
17. Franzoso, G., L. Carlson, K. Brown, M. B. Daucher, P. Bressler, and U. Siebenlist. 1996. Activation of the serum response factor by p65/NF-κB. EMBO J. 15:3403-3412.
18. Galang, C. K., J. J. Garcia-Ramirez, P. A. Solski, J. K. Westwick, C. J. Der, N. N. Neznanov, R. G. Oshima, and C. A. Hauser. 1996. Oncogenic Neu/ ErbB-2 increases Ets, AP-1, and NF-κB dependent gene expression, and inhibiting Ets activation blocks neu-mediated cellular transformation J. Biol. Chem. 271:7992-7998.
19. Gaub, M. P., M. Bellard, I. Scheuer, P. Chambon, and P. Sassone-Corsi 1990. Activation of the ovalbumin gene by the estrogen receptor involves fos-jun complex. Cell 63:1267-1276.
20. Gutman, A., and B. Wasylyk. 1990. The collagenasc gene promoter contains a TPA and oncogenc-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J. 9:2241-2246.
21. Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:352-364.
22. Hansen, S. K., C. Nerlov, U. Zabel, P. Verde, M. Johnsen, P. A. Baeuerle, and F. Blasi. 1992. A novel complex between the p65 subunit of NF-κB and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J. 11:205-213.
23. Harlow, E., and D. Lane. 1988. Antibodies, a laboratory manual, p. 421-470. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
24. Henkel, T., T. Machleidt, I. Alkalay, M. Kronke, Y. Ben-Neriah, and P. A. Baeuerle. 1993. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB. Nature 365:182-185.
25. Higgins, K. A., J. R. Perez, T. A. Coleman, K. Dorshkind, W. A. McComas, U. L. Sarmiento, C. A. Rosen, and R. Narayanan. 1993. Antiscnse inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA 90:9901-9905.
26. Horwitz, K. B. 1993. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res. Treal. 26:119-130.
27. Inoue, J., L. D. Kerr, A. Kakizuka, and I. M. Verma. 1992. IκBγ, a 70 kd protein identical to the c-terminal half of p110 NF-κB: a member of the IκB family. Cell 68:1109-1120.
28. Johnston, S. R. D., G. Saccani-Jotti, I. E. Smith, J. Salter, J. Newby, M. Coppen, S. R. Ebbs, and M. Dowsed. 1995. Changes in estrogen, progester-one receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 55:3331-3338.
29. Kalkhoven, E., S. Wissink, P. T. van der Saag, and B. van der Burg. 1996 Negative interaction between the RelA(p65) subunit of NF-κB and the progesterone receptor. J. Biol. Chem. 271:6217-6224.
30. Kastner, P., A. Krust, B. Turcotte. U. Stropp, L. Tora, H. Gronemeyer, and P. Chambon. 1990. Two distinct estrogen regulated promoters generate transcripts encoding the two functionally different human progesterone receptors forms A and B. EMBO J. 9:1603-1614.
31. Kerr, L. D., D. B. Miller, and L. M. Matrisian. 1990. TGF-β1 inhibition of transin/stromelysin gene expression is mediated through a fos binding sequence. Cell 61:267-278.
32. Liotta, L. A., P. S. Steeg, and W. G. Stetler-Stevenson. 1991. Cancer metastasis and angiogencsis: an imbalance of positive and negative reculation. Cell 64:327-336.
33. Liu, Z.-G., H. Hsu, D. V. Goeddel, and M. Karin. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87:565-576.
34. 1. Cancer Res. 54:1587-1595.
35. Lyle, R., E. M. A. Valleley, P.-T. Sharpe, and J. E. Hewitt. 1994. An alternatively spliced transcript, p65Δ2, of the gene encoding the p65 subunit of the transcription factor NF-κB. Gene 138:265-266.
36. Maxwell, S. A., and T. Mukhipadhyay. 1995. A novel NF-κB p65 spliced transcript lacking exons 6 and 7 in a non-small cell lung carcinoma coll liite Gene 166:339-340.
37. McGuire, W. L., G. C. Chamness, and S. A. W. Fuqua. 1991. Estrogen receptor variants in clinical breast cancer. Mol. Endocrinol. 5:1571-1577.
38. Murphy, L. C., and H. Dotzlaw. 1989. Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol. Endocrinol. 3:687-693.
39. Nakanishi, H., R. M. Taylor, F. J. Chrest, T. Masui, K. Utsumi, M. Tatematsu, and A. Passaniti. 1995. Progression of hormone-dependent adenocnrcinoma cells to hormone-independent spindle carcinoma cells in vitro in a clonal spontaneous rat mammary tumor cell line. Cancer Res. 55:399-407.
40. Nakshatri, H., and P. Chambon. 1994. The directly repeated RG(G/T)TCA motifs of the rat and mouse cellular retinol-binding protein II genes are promiscuous binding sites for RAR, RXR, HNF-4, and ARP-1 homo-and heterodimers. J. Biol. Chem. 269:890-902.
41. Nandi, S., R. C. Guzman, and J. Yang. 1995. Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc. Natl. Acad. Sci. USA 92:3650-3657.
42. Narayanan, R., J. F. Klement, S. M. Ruben, K. A. Higgins, and C. A. Rosen. 1992. Identification of a naturally occurring transforming variant of the p65 subunit of NF-κB. Science 256:367-370.
43. Nicholson, S., C. Wright, R. C. Sainsbury, P. Halcrow, P. Kelly, B. Angus, J. R. Farndon, and A. L. Harris. 1990. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J. Steroid Biochem. Mol. Biol. 37:811-814.
44. Osborne, C. K., M. G. Yochmowitz, W. A. Knight III, and W. L. McGuire. 1980. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884-2888.
45. Price, J. E., A. Polyzos, R. D. Zhang, and L. M. Daniels. 1990. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 50:717-721.
46. Ray, A., K. E. Prefontaine, and P. Ray. 1994. Down-modulation of interleukin-6 gene expression by 17 β-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J. Biol. Chem. 269:12940-12946.
47. Ruben, S. M., R. Narayanan, J. F. Klement, C.-H. Chen, and C. A. Rosen. 1992. Functional characterization of the NF-κB p65 transcriptional activator and an alternatively spliced derivative. Mol. Cell. Biol. 12:444-454.
48. Russell, K. S., and M.-C. Hung. 1992. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res. 52: 6624-6629.
49. Santen, R., A. Manni, H. Harvey, and C. Redmond. 1990. Endocrine treatment of breast cancer in women. Endocrine Rev. 11:221-265.
50. Sato, H., and M. Seiki. 1993. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8:395-405.
51. Schulze-Osthoff, K., P. H. Krammer, and W. Droge. 1994. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J. 13:4587-4596.
52. Sharma, H. W., K. Higgins-Sochaski, J. R. Perez, and R. Narayanan. 1995. A DNA motif present in αV integrin promoter exhibits dual binding preference to distinct transcription factors. Anticancer Res. 15:1857-1868.
53. Siebenlist, U., G. Franzoso, and K. Brown. 1994. Structure, regulation and function of NF-κB. Annu. Rev. Cell Biol. 10:405-455.
54. Sommers, C. L., S. W. Byers, E. W. Thompson, J. A. Torri, and E. P. Gelmann. 1994. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res. Treat. 31:325-335.
55. Stein, B., A. S. Baldwin, Jr., D. W. Ballard, W. C. Greene, P. Angel, and P. Herrlich. 1993. Crosscoupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J. 12:3879-3891.
56. Stein, B., and M. X. Yang. 1995. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ. Mol. Cell. Biol. 15:4971-4979.
57. Suyang, H., R. Phillips, I. Douglas, and S. Ghosh. 1996. Role of unphosphorylated, newly synthesized IκBβ in persistent activation of NF-κB. Mol. Cell. Biol. 16:5444-5449.
58. Thompson, E. W., S. Paik, N. Brunner, C. L. Sommers, G. Zugmaier, R. Clarke, T. B. Shima, J. Torri, S. Donahue, M. E. Lippman, G. R. Martin, and R. B. Dickson. 1992. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J. Cell. Physiol. 150:534-544.
59. Thompson, J. E., R. J. Phillips, H. Erdjument-Bromage, P. Tempst, and S. Ghosh. 1995. IκB-β regulates the persistent response in a biphasic activation of NF-κB. Cell 80:573-582.
60. Tora, L., A. Mullick, D. Metzger, M. Ponglikitmongkol, I. Park, and P. Chambon. 1989. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J. 8:1981-1986.
61. Tzukerman, M., X.-K. Zhang, and M. Pfahl. 1991. Inhibition of estrogen receptor activity by the tumor promoter 12-O-tetradecanylphorbol-13-ace-tate: a molecular analysis. Mol. Endocrinol. 5:1983-1992.
62. Van Antwerp, D. J., S. J. Martin, T. Kafri, D. R. Green, and I. M. Verma. 1996. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274:787-789.
63. Verma, I. M., J. K. Stevenson, E. M. Schwarz, D. Van Antwerp, and S. Miyamoto. 1995. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev. 9:2723-2735.
64. Wang, C.-Y., M. W. Mayo, and A. S. Baldwin, Jr. 1996. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274:784-787.
65. Wasylyk, C., A. Gutman, R. Nicholson, and B. Wasylyk. 1991. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J. 10:1127-1134.
66. Wu, M., H, Lee, R. E. Bellas, S. L. Schauer, M. Arsura, D. Katz, M. J. FitzGerald, T. L. Rothstein, D. H. Sherr, and G. E. Sonenshein. 1996. Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J. 15:4682-4690.
67. Yamashita, J. K. Inada, S. Yamashita, S. Matsuo, Y. Nakashima, and M. Ogawa. 1992. Demonstration of a possible link between high grade malignancy in dimethylbenz[a]anthracene-induced rat mammary carcinoma and increased urokinase plasminogen activator content. Int. J. Clin. Lab. Res. 22:165-168.
68. Yoza, B. K., J. Y. Q. Hu, and C. E. McCall. 1996. Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1β and NF-κB activation, but not NF-κE nuclear translocation. J. Biol. Chem. 271: 18306-18309.